Neoplasia papilar intraductal de los conductos biliares con malignizaciónuna entidad diferenciada del colangiocarcinoma con mejor pronóstico. A propósito de tres nuevos casos

  1. Baltasar Pérez Saborido 1
  2. Martín Bailón Cuadrado 1
  3. Mario Rodríguez López 1
  4. Enrique Asensio Díaz 1
  5. Beatriz Madrigal Rubiales 1
  6. A. Barrera Rebollo 1
  1. 1 Hospital Universitario Río Hortega. Valladolid
Revista Española de Enfermedades Digestivas

ISSN: 2340-416 1130-0108

Year of publication: 2017

Volume: 109

Issue: 8

Pages: 592-595

Type: Article

DOI: 10.17235/REED.2017.4835/2016 DIALNET GOOGLE SCHOLAR

More publications in: Revista Española de Enfermedades Digestivas


Introduction: Intraductal papillary neoplasms of the bile duct have been recognized as a differentiated entity to other biliary tumors since 2001. They are characterized by intraductal growth, with or without mucus production, and have malignant potential, although they have a better prognosis than other types of cholangiocarcinoma. Case reports: From January 2010 to August 2015, we included three patients with a confirmed diagnosis of bile duct intraductal papillary neoplasia with malignancy that were treated at our center. Two cases were male and one female with a mean age of 67.3 years. All three patients presented malignancy at the time of diagnosis. One patient was asymptomatic and the diagnosis was reported in the hepatectomy specimen after a liver transplant due to autoimmune hepatitis. The other two patients presented with cholestasis and acute cholangitis and the diagnosis was made based on imaging tests (computed tomography [CT] and magnetic resonance imaging [MRI]) and endoscopic retrograde cholangiopancreatography (ERCP) with brushing and a biopsy. The treatment in both cases was surgical with a left hepatectomy, and resection of the left bile duct and segment I. They did not receive adjuvant treatment. None of the cases had recurrence of the disease. Discussion: Malignant intraductal papillary neoplasias of the biliary tract represent a different entity of cholangiocarcinoma with a better prognosis. Its diagnosis is based on imaging tests and histology by ERCP. The treatment is surgical, achieving a high rate of success with a low relapse rate.